Trinomab is building a robust pipeline using state-of-the-art fully native human monoclonal antibody science. The company is focused on developing innovative treatments that will benefit patients around the world.
| Product code | Indications | Target | Pre-clinical | phase I | phase 2 | phase 3 | Registration |
| TNM001 | Prevention of RSV infection | RSV Pre-F protein | |||||
| TNM002 | Prevention of tetanus | Tetanus toxin | |||||
| TNM005 | Prevention and treatment of VZV infection | VZV gH/gL protein | |||||
| TNM006 | hCMV infection (prevention) | human cytomegalovirus | |||||
| TNM009 | cancer pain, joint pain | NGF | |||||
| TNM030 | Bacterial infectious shock | Hla toxin | |||||
| TNM039 | Rabies prevention | Rabies virus |
| Product code | Indications | Target | Pre-clinical | phase I | phase 2 | phase 3 | Registration |
| TNM001 | Prevention of RSV infection | RSV Pre-F protein | |||||
| TNM002 | Prevention of tetanus | Tetanus toxin | |||||
| TNM005 | Prevention and treatment of VZV infection | VZV gH/gL protein | |||||
| TNM006 | hCMV infection (prevention) | human cytomegalovirus | |||||
| TNM009 | cancer pain, joint pain | NGF | |||||
| TNM030 | Bacterial infectious shock | Hla toxin | |||||
| TNM039 | Rabies prevention | Rabies virus |
| Product code | Indications | Target | Pre-clinical | phase I | phase 2 | phase 3 | Registration |
| TNM001 | Prevention of RSV infection | RSV Pre-F protein | |||||
| TNM002 | Prevention of tetanus | Tetanus toxin | |||||
| TNM005 | Prevention and treatment of VZV infection | VZV gH/gL protein | |||||
| TNM006 | hCMV infection (prevention) | human cytomegalovirus | |||||
| TNM009 | cancer pain, joint pain | NGF | |||||
| TNM030 | Bacterial infectious shock | Hla toxin | |||||
| TNM039 | Rabies prevention | Rabies virus |
| Product code | Indications | Target | Pre-clinical | phase I | phase 2 | phase 3 | Registration |
| TNM001 | Prevention of RSV infection | RSV Pre-F protein | |||||
| TNM002 | Prevention of tetanus | Tetanus toxin | |||||
| TNM005 | Prevention and treatment of VZV infection | VZV gH/gL protein | |||||
| TNM006 | hCMV infection (prevention) | human cytomegalovirus | |||||
| TNM009 | cancer pain, joint pain | NGF | |||||
| TNM030 | Bacterial infectious shock | Hla toxin | |||||
| TNM039 | Rabies prevention | Rabies virus |
| Product code | Indications | Target | Pre-clinical | phase I | phase 2 | phase 3 | Registration |
| TNM001 | Prevention of RSV infection | RSV Pre-F protein | |||||
| TNM002 | Prevention of tetanus | Tetanus toxin | |||||
| TNM005 | Prevention and treatment of VZV infection | VZV gH/gL protein | |||||
| TNM006 | hCMV infection (prevention) | human cytomegalovirus | |||||
| TNM009 | cancer pain, joint pain | NGF | |||||
| TNM030 | Bacterial infectious shock | Hla toxin | |||||
| TNM039 | Rabies prevention | Rabies virus |
| Product code | Indications | Target | Pre-clinical | phase I | phase 2 | phase 3 | Registration |
| TNM001 | Prevention of RSV infection | RSV Pre-F protein | |||||
| TNM002 | Prevention of tetanus | Tetanus toxin | |||||
| TNM005 | Prevention and treatment of VZV infection | VZV gH/gL protein | |||||
| TNM006 | hCMV infection (prevention) | human cytomegalovirus | |||||
| TNM009 | cancer pain, joint pain | NGF | |||||
| TNM030 | Bacterial infectious shock | Hla toxin | |||||
| TNM039 | Rabies prevention | Rabies virus |
| Product code | Indications | Target | Pre-clinical | phase I | phase 2 | phase 3 | Registration |
| TNM001 | Prevention of RSV infection | RSV Pre-F protein | |||||
| TNM002 | Prevention of tetanus | Tetanus toxin | |||||
| TNM005 | Prevention and treatment of VZV infection | VZV gH/gL protein | |||||
| TNM006 | hCMV infection (prevention) | human cytomegalovirus | |||||
| TNM009 | cancer pain, joint pain | NGF | |||||
| TNM030 | Bacterial infectious shock | Hla toxin | |||||
| TNM039 | Rabies prevention | Rabies virus |
